Clinical trial
The Potential of Curcumin Extract as an Adjuvant Therapy in the Eradication of Typhoid Carriers Among Food Handlers of the Free Nutritious Meal Program (Program Makan Bergizi Gratis): Carrier Screening Followed by a Randomized, Double-Blind, Placebo-Controlled Trial
NCT07908030 is registered in ClinicalTrials.gov with Universitas Sebelas Maret as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Potential of Curcumin Extract as an Adjuvant Therapy in the Eradication of Typhoid Carriers Among Food Handlers of the Free Nutritious Meal Program (Program Makan Bergizi Gratis): Carrier Screening Followed by a Randomized, Double-Blind, Placebo-Controlled Trial
- Lead sponsor
- Universitas Sebelas Maret
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- November 2, 2026
- Completion date
- October 22, 2027
- Enrollment
- 100 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
salmonella typhi infection, typhoid carrier, typhoid fever
Arms
As registered; 2 arms.
-
Ciprofloxacin + Curcumin Extract
Culture-confirmed typhoid carriers take ciprofloxacin 500 mg by mouth twice daily plus curcumin extract 1,000 mg per day by mouth for 28 days.
-
Ciprofloxacin + Placebo
Culture-confirmed typhoid carriers take ciprofloxacin 500 mg by mouth twice daily plus placebo capsules (amylum) for 28 days. The placebo capsules look the same as the curcumin capsules.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Proportion of participants with negative Salmonella Typhi culture (eradication)
A rectal swab is cultured on Salmonella Shigella Agar. Suspected colonies are confirmed with IMViC biochemical tests. Eradication means no growth of Salmonella Typhi. The proportion is compared between the two arms.
Lead sponsor's other trials
Universitas Sebelas Maret, most recent start first.
+24 more trials
Similar trials
Same condition (Typhoid Fever) and phase, most recent start first.
+9 more trials See the condition page